Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928325 | 0.98 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2NPSR1MEN1 | |
| SCHEMBL1928674 | 0.93 | — | — | |
| SCHEMBL7218326 | 0.88 | — | — | |
| SCHEMBL9064096 | 0.78 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1SMN1; SMN2 | |
| SCHEMBL9129957 | 0.78 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1SMN1; SMN2 | |
| SCHEMBL5608734 | 0.78 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1SMN1; SMN2 | |
| SCHEMBL9129967 | 0.78 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2NPSR1SMN1; SMN2 | |
| SCHEMBL8896239 | 0.77 | ALDH1A1 (0.42) | HCAR2NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL9540359 | 0.77 | ALDH1A1 (0.42) | HCAR2NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL38251 | 0.76 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003699-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-23 | — | — | US | disclosed |
| US-7956010-B2 | Amide compound and use thereof for controlling plant diseases | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-07 | — | — | US | disclosed |
| EP-2240020-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | Pgx Health, Llc (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100048701-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2154124-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
| EP-2151432-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009089425-A1 | INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS | PGXHEALTH LLC (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2007120972-A2 | METHOD TO TREAT SICKLE CELL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-0564960-A1 | Imidazopyridines as angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048701-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | CYC1, CBR3, CBR1 | HCAR2 581/4885KEAP1 392/4885NFE2L2 237/4885 |
| US-20100105647-A1 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES | CYC1, CBR3, CBR1 | HCAR2 854/4885KEAP1 605/4885NFE2L2 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.